Sheeba Koshy Thomas, M.D.

Peer-Reviewed Articles

1. Haider AA, Marcoux C, Milton DR, Tanner MR, Bashir Q, Smallbone P, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Mohamedi AH, Siddiqui UR, Aljawai Y, Kebriaei P, Lee HC, Ye C, Patel KK, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Pasvolsky O. Lenalidomide maintenance after delayed or salvage autologous stem cell transplantation. Leuk Lymphoma:1-9, 2026. e-Pub 2026. PMID: 41608977.
2. Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Saeed A, Haider AA, Ramdial J, Irfan S, YagoNieto, Tang G, Aljawai Y, Kebriaei P, Lee HC, Patel KK, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Pasvolsky O. Post-transplant outcomes in IgD multiple myeloma:a propensity score-matched analysis. Transplant Cell Ther, 2025. e-Pub 2025. PMID: 41421540.
3. Pasvolsky O, Marcoux C, Milton DR, Haider AA, Tanner MR, Bashir Q, Srour S, Saini N, Smallbone P, Lin P, Ramdial J, Nieto Y, Mohamedi AH, Siddiqui UR, Jamil A, Tang G, Aljawai Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Results of delayed or salvage autologous hematopoietic stem cell transplantation for multiple myeloma. Bone Marrow Transplant, 2025. e-Pub 2025. PMID: 41350936.
4. Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Patel A, Khan HN, Ramdial J, Nieto Y, Tang G, Haider A, Aljawai Y, Kebriaei P, Lee HC, Ye C, Patel KK, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Pasvolsky O. Outcomes of Patients with Multiple Myeloma with deletion 1p Following Autologous Stem Cell Transplant. Transplant Cell Ther 31(10):804.e1-804.e9, 2025. e-Pub 2025. PMID: 40752590.
5. Pasvolsky O, Marcoux C, Milton DR, Rafaeli N, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Mohamedi AH, Deen AF, Aljawai Y, Lee HC, Patel KK, Becnel MR, Kebriaei P, Thomas SK, Orlowski RZ, Champlin R, Shpall EJ, Qazilbash MH. Outcomes of Multiple Myeloma Patients With Prior Solid Tumors Undergoing Autologous Transplantation. Transplant Cell Ther 31(8):565.e1-565.e9, 2025. e-Pub 2025. PMID: 40383197.
6. Chohan KL, Weber DM, Feng L, Wang LM, Neelapu SS, Olsem J, Johnson RJ, Morales de Partovi C, Orlowski RZ, Thomas SK. Phase I study of pomalidomide in relapsed or refractory Waldenstrom macroglobulinaemia. Br J Haematol 207(1):244-248, 2025. e-Pub 2025. PMID: 40361301.
7. Becking AL, van de Mortel JPM, Tomkins O, Flinsenberg TWH, Japzon N, Kersten MJ, Khwaja J, Kuipers S, Levenga H, McKeague S, Opat S, Salvaris RT, Seif S, Thomas SK, Vrancken AFJE, D'Sa S, Minnema MC, Vos JMI. Zanubrutinib in Bing Neel syndrome: efficacy and tolerability. Leukemia 39(5):1260-1264, 2025. e-Pub 2025. PMID: 40164717.
8. Sawalha Y, Sarosiek S, Welkie RL, Seif S, Thapa S, Zanwar S, Cahill K, Treitman R, Shah H, Arora S, Pongas G, Winter A, Major A, Riedell PA, Palomba ML, Kapoor P, Grajales-Cruz A, Shain KH, Thomas SK, Castillo JJ. Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia treated with venetoclax: a multicenter retrospective analysis. Blood Cancer J 15(1):65, 2025. e-Pub 2025. PMID: 40234394.
9. Saha S, Rehman L, Rehman A, Darbaniyan F, Weber DM, Becnel M, Gaballa MR, Thomas SK, Lee HC, Chang CC, Arora R, Menges M, Corallo S, Davila ML, Locke FL, Tanner MR, Neelapu SS, Shpall EJ, Flowers CR, Orlowski RZ, Jenq RR, Jain MD, Peterson C, Hansen DK, Saini NY, Patel KK. Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel. Blood Adv 9(14):3429-3440, 2025. e-Pub 2025. PMID: 40198765.
10. Pasvolsky O, Abid MB, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Jatoi A, Khan HN, Lin P, Ramdial J, Nieto Y, Tang G, Siddiqui U, Aljawai Y, Kebriaei P, Lee HC, Patel KK, Gaballa MR, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Outcomes of patients with multiple myeloma undergoing autologous transplant with suboptimal pretransplant response. Br J Haematol 206(6):1730-1736, 2025. e-Pub 2025. PMID: 40159289.
11. George, M, Mustafayev, K, Ahmed, S, Thomas, SK, Jiang, Y, Patel, K, Torres, HA. Direct-Acting Antivirals Induce Lymphoproliferative Disease Response in HCV-Infected Patients With Indolent B-Cell Non-Hodgkin’s Lymphoma. Hematological Oncology 43(2), 2025. e-Pub 2025. PMID: 39921915.
12. Pasvolsky O, Marcoux C, Wang Z, Milton DR, Pal B, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Syed N, Aljawai Y, Lee HC, Patel KK, Becnel MR, Ye C, Kebriaei P, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther 31(3):166.e1-166.e9, 2025. e-Pub 2025. PMID: 39746546.
13. Moreno Rueda LY, Wang H, Akagi K, Dang M, Vora A, Qin L, Lee HC, Patel KK, Lin P, Mery DE, Zhan F, Shaughnessy Jr JD, Yi Q, Song Y, Jiang B, Gillison ML, Thomas SK, Weber DM, Diao L, Wang J, Kuiatse I, Manasanch EE, Symer DE, Orlowski RZ. Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets. Cell Rep Med 6(2), 2025. PMID: 39855192.
14. Marcoux C, Pasvolsky O, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Lee HC, Patel KK, Kebriaei P, Ahmed A, Aljawai Y, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Real-World Outcomes of Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma With Deletion 17p. Transplant Cell Ther 31(1):12.e1-12.e10, 2025. e-Pub 2025. PMID: 39448031.
15. Pasvolsky, O, Marcoux, C, Milton, D, Pal, B, Tanner, MR, Bashir, Q, Srour, S, Lee, J, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Aljawai, YM, Kebriaei, P, Becnel, M, Lee, HC, Patel, K, Thomas, SK, Orlowski, R, Shpall, EJ, Champlin, RE, Qazilbash, MH. Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 39482325.
16. Manzar GS, Dudzinski SO, Yoder AK, Seo A, Nasr LF, Rafei H, Becnel MR, Patel KK, Lee HC, Kaufman GP, Gaballa MM, Ye JC, Saini N, Thomas SK, Amini B, Orlowski RZ, Dabaja BS, Pinnix CC, Gunther JR, Wu SY, Fang PQ. Outcome of Patients With Central Nervous System Multiple Myeloma (CNS-MM) Treated With CNS-Directed Radiation Therapy. Clin Lymphoma Myeloma Leuk 25(4):271-284, 2024. e-Pub 2024. PMID: 39709251.
17. Szymura SJ, Wang L, Zhang T, Cha SC, Song J, Dong Z, Anderson A, Oh E, Lee V, Wang Z, Parshottam S, Rao S, Olsem JB, Crumpton BN, Lee HC, Manasanch EE, Neelapu S, Kwak LW, Thomas SK. Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial. Nat Commun 15(1):6874, 2024. e-Pub 2024. PMID: 39128904.
18. Pasvolsky O, Marcoux C, Dai J, Milton DR, Tanner MR, Syed N, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Lee HC, Gaballa MR, Patel KK, Kebriaei P, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma over Three Decades. Transplant Cell Ther 30(8):772.e1-772.e11, 2024. e-Pub 2024. PMID: 38852784.
19. Pasvolsky O, Wang Z, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Kebriaei P, Aljawai Y, Khan HN, Lee HC, Ye C, Patel KK, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation. Blood Cancer J 14(1):82, 2024. e-Pub 2024. PMID: 38760362.
20. Pasvolsky O, Pasyar S, Bassett RL, Khan HN, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation. Cancer 130(9):1663-1672, 2024. e-Pub 2023. PMID: 38127583.
21. Alzahrani K, Pasvolsky O, Wang Z, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH. Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation. Br J Haematol 204(5):1944-1952, 2024. e-Pub 2024. PMID: 38448009.
22. Pasvolsky O, Ghanem S, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Khan HN, Kebriaei P, Lee HC, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience. Blood Cancer J 14(1):4, 2024. e-Pub 2024. PMID: 38199987.
23. Fang P, Pinnix CC, Wu SY, Lee HC, Patel KK, Saini N, Becnel MR, Kaufman G, Thomas SK, Orlowski RZ, Amini B, Lin P, Dabaja BS, Gunther JR. Management and Outcomes of Patients with Refractory Solitary Plasmacytoma after Treatment with Definitive Radiation Therapy. Int J Radiat Oncol Biol Phys. e-Pub 2023. PMID: 38070713.
24. Pasvolsky O, Ghanem S, Milton DR, Masood A, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma. Transplant Cell Ther 29(12):757-762, 2023. e-Pub 2023. PMID: 37673125.
25. Pasvolsky O, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Saeed A, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience. Am J Hematol 98(10):1571-1578, 2023. e-Pub 2023. PMID: 37461327.
26. Kwak L, Szymura S, Wang L, Zhang T, Cha SC, Dong Z, Anderson A, Oh E, Lee V, Wang Z, Parshottham S, Rao S, Olsem J, Crumpton B, Lee H, Manasanch E, Neelapu S, Thomas S. First-in-human clinical trial of personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma. Res Sq, 2023. e-Pub 2023. PMID: 37790486.
27. Chiu CY, Ahmed S, Thomas SK, Wang LS, Mustafayev K, Fayad LE, Wierda WG, Khawaja F, Torres HA. Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors. Clin Lymphoma Myeloma Leuk 23(8):610-615, 2023. e-Pub 2023. PMID: 37150651.
28. Pasvolsky O, Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Tewari P, Crawford-Suber L, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of young adults (aged = 40 years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant. Br J Haematol 202(4):866-873, 2023. e-Pub 2023. PMID: 37376789.
29. Dang M, Wang R, Lee HC, Patel KK, Becnel MR, Han G, Thomas SK, Hao D, Chu Y, Weber DM, Lin P, Lutter-Berka Z, Berrios Nolasco DA, Huang M, Bansal H, Song X, Zhang J, Futreal A, Moreno Rueda LY, Symer DE, Green MR, Rojas Hernandez CM, Kroll M, Afshar-Khargan V, Ndacayisaba LJ, Kuhn P, Neelapu SS, Orlowski RZ, Wang L, Manasanch EE. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease. Cancer Cell 41(6):1032-1047.e4, 2023. e-Pub 2023. PMID: 37311413.
30. Pasvolsky O, Saliba RM, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant. Br J Haematol 201(4):e37-e41, 2023. e-Pub 2023. PMID: 36916461.
31. Pasvolsky O, Milton DR, Rauf M, Ghanem S, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Rezvani K, Champlin R, Shpall EJ, Lin P, Qazilbash MH. Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients. Blood Cancer J 13(1):68, 2023. e-Pub 2023. PMID: 37137874.
32. Shank BR, Primeaux B, Yeung EK, Horowitz SB, Lee IY, Roccograndi L, Feng L, Kaufman GP, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Weber DM, Becnel MR, Thomas SK. Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospective Analysis. Clin Lymphoma Myeloma Leuk 23(4):279-290, 2023. e-Pub 2023. PMID: 36797154.
33. Afrough A, Alsfeld LC, Milton DR, Delgado R, Popat UR, Nieto Y, Kebriaei P, Oran B, Saini N, Srour S, Hosing C, Cheema FH, Ahmed S, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Weber DM, Orlowski RZ, Pinnix CC, Dabaja BS, Thomas SK, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Long-term outcomes of allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma. Transplant Cell Ther 29(4):264.e1-264.e9, 2023. e-Pub 2023. PMID: 35605883.
34. Pasvolsky O, Gaballa MR, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Tang G, Lin P, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience: Transplant in t(4;14) MM. Transplant Cell Ther 29(4):260.e1-260.e6, 2023. e-Pub 2023. PMID: 36646323.
35. Chiu CY, Patel K, Thomas SK, Khawaja F, Dailey Garnes NJM, Lee HC, Ohanian M, Jiang Y, Wang LS, Hwang JP, Torres HA. Hepatitis B virus reactivation in patients with past HBV infection receiving anti-CD38 monoclonal antibodies. Hepatol Int 17(2):509-511, 2023. e-Pub 2023. PMID: 36477692.
36. D'Sa, S, Matous, JV, Advani, RH, Buske, C, Castillo, JJ, Gatt, ME, Kapoor, P, Kersten, MJ, Leblond, V, Leiba, M, Lia Palomba, M, Paludo, J, Qiu, LG, Sarosiek, S, Shadman, M, Talaulikar, D, Tam, CS, Tedeschi, A, Thomas, SK, Tohidi-Esfahani, I, Trotman, J, Varettoni, M, Vos, JM, García-Sanz, R, San-Miguel, J, Dimopoulos, MA, Treon, SP, Kastritis, E. Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients. Seminars in hematology 60(2):80-89, 2023. e-Pub 2023. PMID: 37147252.
37. Buske C, Castillo JJ, Abeykoon JP, Advani R, Arulogun SO, Branagan AR, Cao X, D'Sa S, Hou J, Kapoor P, Kastritis E, Kersten MJ, LeBlond V, Leiba M, Matous JV, Paludo J, Qiu L, Tam CS, Tedeschi A, Thomas SK, Tohidi-Esfahani I, Varettoni M, Vos JM, Garcia-Sanz R, San-Miguel J, Dimopoulos MA, Treon SP, Trotman J. Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients. Semin Hematol 60(2):73-79, 2023. e-Pub 2023. PMID: 37099027.
38. Qiu L, Nwogbo OV, Medeiros LJ, Thakral B, Li S, Xu J, You MJ, Wang W, Quesada AE, Ramos CB, McDonnell TJ, Thomas SK, Lin P. Lymphoplasmacytic Lymphoma with IgG or IgA Paraprotein: A Study of 29 Cases including Cases that Can Mimic Plasma Cell Neoplasms. Hum Pathol 130:47-57, 2022. e-Pub 2022. PMID: 36244464.
39. Pasvolsky O, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Tang G, Saini N, Ramdial J, Masood A, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Lenalidomide-Based Maintenance After Autologous Hematopoietic Stem Cell Transplant for Patients with High-Risk Multiple Myeloma. Transplant Cell Ther 28(11):752.e1-752.e6, 2022. e-Pub 2022. PMID: 35940528.
40. Kalariya, N, Ferreri, C, Dillard, C, Hawkins, MC, Manasanch, EE, Lee, HC, Weber, DM, Thomas, SK, Steiner, RE, Hosing, C, Qazilbash, MH, Popat, UR, Orlowski, R, Hildebrandt, MA, Patel, K. CT-511 Clinical Characteristics and Response Outcomes in Older Multiple Myeloma Patients Who Received Idecabtagene Vicleucel. Clinical Lymphoma, Myeloma and Leukemia 22:S446, 2022. e-Pub 2022. PMID: 36164224.
41. Pasvolsky, O, Milton, D, Rauf, M, Ghanem, S, Masood, A, Mohamedi, A, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Ramdial, JL, Nieto, Y, Tang, G, Lee, HC, Patel, K, Kebriaei, P, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Lin, P, Qazilbash, MH. MM-403 Impact of Clonal Plasma Cells in Autografts on the Outcome of High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant. Clinical Lymphoma, Myeloma and Leukemia 22:S421-S422, 2022. e-Pub 2022. PMID: 36164172.
42. Gaballa MR, Ma J, Rauf M, Bassett R, Pasvolsky O, Tanner MR, Bashir Q, Srour SA, Saini N, Ramdial J, Nieto Y, Murphy R, Rezvani K, Tang G, Lin P, Lee HC, Patel KK, Ullah MR, Kaufman GP, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Shpall EJ, Champlin RE, Orlowski RZ, Qazilbash MH. KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. Bone Marrow Transplant 57(7):1142-1149, 2022. e-Pub 2022. PMID: 35523847.
43. Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke C. Clinical Efficacy of Sequencing CD38 targeting monoclonal antibodies in Relapsed Refractory Multiple Myeloma: A multi-institutional experience. Am J Hematol 97(7):E276-E280, 2022. e-Pub 2022. PMID: 35472167.
44. Afrough A, Pasvolsky O, Ma J, Srour S, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Delgado R, Ullah MR, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of Induction with VCD vs. VRD on the Outcome of Patients with Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther 28(6):307.e1-307.e8, 2022. e-Pub 2022. PMID: 35331973.
45. Patel KK, Shah JJ, Feng L, Lee HC, Manasanch EM, Olsem J, Morphey A, Huo XJ, Thomas SK, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ. Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Post-transplant Myeloma Patients. Clin Cancer Res 28(7):1277-1284, 2022. e-Pub 2022. PMID: 34992070.
46. Gaballa MR, Ma J, Tanner MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini NY, Ramdial JL, Nieto Y, Murphy R, Rezvani K, Tang G, Lee HC, Patel KK, Kaufman GP, Manasanch EE, Ullah MR, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma 63(3):1-12, 2022. e-Pub 2022. PMID: 34686083.
47. Patel R, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Daher M, Mehta R, Srour S, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Shpall ES, Champlin RE, Saini N, Qazilbash MH. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis. Am J Hematol 96(12):E455-E457, 2021. e-Pub 2021. PMID: 34559916.
48. Srour SA, Milton DR, Bashir Q, Nieto Y, Saini N, Daher M, Ramdial J, Im J, Hosing C, Delgado R, Manasanch E, Lee HC, Thomas S, Kaufman G, Patel K, Popat U, Weber D, Orlowski R, Shpall E, Champlin RE, Qazilbash MH. Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica 106(12):3211-3214, 2021. e-Pub 2021. PMID: 34407606.
49. Kunacheewa C, Feng L, Manasanch EE, Bashir Q, Patel KK, Mehta R, Kaufman GP, Srour S, Saini N, Iyer SP, Thomas SK, Weber DM, Orlowski RZ, Qazilbash MH, Lee HC. Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy. Br J Haematol 193(3):e23-e26, 2021. e-Pub 2021. PMID: 33748943.
50. Wang, Y, Gali, VL, Xu-Monette, Z, Sano, D, Thomas, SK, Weber, DM, Zhu, F, Fang, X, Deng, MM, Zhang, M, Hagemeister, FB, Li, Y, Orlowski, R, Lee, HC, Young, KH. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia. Neoplasia (United States) 23(4):361-374, 2021. e-Pub 2021. PMID: 33735664.
51. Wang Y, Gali VL, et al XZ. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia. Neoplasia 23(4):361-374, 2021. e-Pub 2021.
52. Manasanch EE, Berrios D, Fountain E, Claussen CM, Chuang T, Kaufman G, Amini B, Bashir Q, Nieto Y, Qazilbash M, Patel K, Thomas SK, Weber DM, Berkova Z, Toruner G, Lin P, Feng L, Lee HC, Orlowski RZ, Kunacheewa C. Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies. Br J Haematol 192(4):e115-e120, 2021. e-Pub 2021. PMID: 33486754.
53. Manasanch EE, Kunacheewa C, Claussen CM, Lee HC, Thomas SK, Gunther J, Pinnix CC, Dabaja BS, Amini B, Alexanian R, Orlowski RZ, Dong W, Feng L, Weber DM. Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up. Blood Cancer J 11(2):17, 2021. e-Pub 2021. PMID: 33563896.
54. Manasanch EE, Mulanovich V, Manzano JG, Gaeta MS, Becnel M, Kaufman GP, Lee HC, Amini B, Thomas SK, Iyer SP, Weber DM, Berkova Z, Flowers CR, Orlowski RZ, Patel KK. SARS-CoV-2 in multiple myeloma: initial observation and management. Leuk Lymphoma 61(11):2763-2766, 2020. e-Pub 2020. PMID: 33167721.
55. Saini N, Bashir Q, Milton DR, Tang G, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Mehta R, Srour S, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Adv 4(19):4834-4837, 2020. e-Pub 2020. PMID: 33027527.
56. Thomas SK. Waldenström Macroglobulinemia - 2020 Update on Management and Future Directions. Clin Lymphoma Myeloma Leuk 20 Suppl 1:S39-S41, 2020. e-Pub 2020. PMID: 32862863.
57. Elhammali A, Amini B, Ludmir EB, Gunther JR, Milgrom SA, Pinnix CC, Andraos T, Yoder A, Weber D, Orlowski R, Manasanch E, Patel K, Strati P, Nair R, Lee HC, Thomas S, Iyer S, Kaufmann G, Garg N, Dabaja BS. New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity. Haematologica 105(7):e355-e357, 2020. e-Pub 2020. PMID: 31919088.
58. Cordas Dos Santos DM, Saliba RM, Patel R, Bashir Q, Saini N, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Popat U, Ahmed H, Lee HC, Manasanch EE, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 26(6):1077-1083, 2020. e-Pub 2020. PMID: 31786242.
59. Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Olsem J, Crumpton B, Morphey A, Berkova Z, Feng L, Orlowski RZ. Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma. Haematologica 105(5):e242-e245, 2020. e-Pub 2020. PMID: 31413094.
60. Kunacheewa C, Lee HC, Patel K, Thomas S, Amini B, Srour S, Bashir Q, Nieto Y, Qazilbash MH, Weber DM, Feng L, Orlowski RZ, Lin P, Manasanch EE. Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study. Clin Lymphoma Myeloma Leuk 20(5):e221-e238, 2020. e-Pub 2020. PMID: 32037287.
61. Owen RG, McCarthy H, Rule S, D'Sa S, Thomas SK, Tournilhac O, Forconi F, Kersten MJ, Zinzani PL, Iyengar S, Kothari J, Minnema MC, Kastritis E, Aurran-Schleinitz T, Cheson BD, Walter H, Greenwald D, Chen DY, Frigault MM, Hamdy A, Izumi R, Patel P, Wei H, Lee SK, Mittag D, Furman RR. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol 7(2):e112-e121, 2020. e-Pub 2020. PMID: 31866281.
62. Lee HC, Shah JJ, Feng L, Morphey A, Johnson RJ, Wesson ET, Wang ML, Alexanian R, Thomas SK, Orlowski RZ, Weber DM. A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Am J Hematol 94(12):E319-E322, 2019. e-Pub 2019. PMID: 31489991.
63. Raab MS, Thomas SK, Ocio EM, Guenther A, Goh YT, Talpaz M, Hohmann N, Zhao S, Xiang F, Simon C, Vanasse KG, Kumar SK. The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma. Leukemia 33(12):2924-2933, 2019. e-Pub 2019. PMID: 31092894.
64. Varma A, Sui D, Milton DR, Tang G, Saini N, Hasan O, Mukherjee A, Joseph JJ, Bashir Q, Rondon G, Srour S, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mehta R, Khouri IF, Ahmed H, Iyer S, Weber DM, Thomas SK, Manasanch E, Lee HC, Patel K, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. Biol Blood Marrow Transplant. e-Pub 2019. PMID: 31881283.
65. Saini N, Ma J, Milton DR, Patel R, Varma A, Bashir Q, Delgado R, Mukherjee A, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Tang G, Mehta R, Srour S, Khouri IF, Iyer S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. Clin Cancer Res 25(22):6781-6787, 2019. e-Pub 2019. PMID: 31481508.
66. Lee HC, Shah JJ, Feng L, Manasanch EE, Lu R, Morphey A, Crumpton B, Patel KK, Wang ML, Alexanian R, Thomas SK, Weber DM, Orlowski RZ. A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Blood Cancer J 9(10):80, 2019. e-Pub 2019. PMID: 31575851.
67. Tabchi S, Nair R, Kunacheewa C, Patel KK, Lee HC, Thomas SK, Amini B, Ahmed S, Mehta RS, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ, Alexanian R, Feng L, Manasanch EE. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia. Clin Lymphoma Myeloma Leuk 19(9):560-569, 2019. e-Pub 2019. PMID: 31201134.
68. Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Mukherjee A, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia. Ann Hematol 98(9):2233-2235, 2019. e-Pub 2019. PMID: 31243571.
69. Elhammali A, Milgrom SA, Amini B, Gunther JR, Yoder A, Ludmir EB, Moon B, Weber DM, Thomas SK, Garg N, Manasanch EE, Patel KK, Orlowski RZ, Lee HC, Bird JE, Satcher R, Lin P, Pinnix CC, Dabaja BS. Postoperative Radiotherapy for Multiple Myeloma of Long Bones: Should the Entire Rod Be Treated?. Clin Lymphoma Myeloma Leuk 19(8):e465-e469, 2019. e-Pub 2019. PMID: 31133526.
70. Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol 6(5):e266-e275, 2019. e-Pub 2019. PMID: 30910541.
71. Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Feng L, Berkova Z, Hildebrandt M, Orlowski RZ. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial. Lancet Haematol 5(12):e628-e640, 2018. e-Pub 2018. PMID: 30501870.
72. Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. Am J Hematol. e-Pub 2018. PMID: 30548467.
73. Gowda L, Shah M, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta R, Weber DM, Lee HC, Manasanch EE, Shah A, Thomas SK, Parmar S, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplant. e-Pub 2018. PMID: 30446740.
74. Afrough A, Saliba RM, Hamdi A, Hoeber DM, Thomas S, Orlowski RZ, Cnhar M, Varma A, Cornelison AM, Rondon G, Parmar S, Shah ND, Bashir Q, Hosing C, Popat U, Whamplin RE, Qazilbash MH. Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 24(11):2197-2203, 2018. e-Pub 2018. PMID: 30016656.
75. Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan-based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol. e-Pub 2018. PMID: 30300461.
76. Chaudhry M, Steiner R, Claussen C, Patel K, Lee H, Weber D, Thomas S, Feng C, Amini B, Orlowski R, Feng L, Manasanch EE. Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenström's macroglobulinemia. Leuk Lymphoma:1-7. e-Pub 2018. PMID: 30227761.
77. Ni H, Shirazi F, Baladandayuthapani V, Lin H, Kuiatse I, Wang H, Jones RJ, Berkova Z, Hitoshi Y, Ansell SM, Treon SP, Thomas SK, Lee HC, Wang Z, Davis RE, Orlowski RZ. Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res. e-Pub 2018. PMID: 30126942.
78. Hu B, Thall P, Milton DR, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MH. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leuk Lymphoma:1-11. e-Pub 2018. PMID: 30032678.
79. Zhang X, Lee HC, Shirazi F, Baladandayuthapani V, Lin H, Kuiatse I, Wang H, Jones RJ, Berkova Z, Singh RK, Lu J, Qian Y, Raina K, Coleman KG, Crews CM, Li B, Wang H, Hailemichael Y, Thomas SK, Wang Z, Davis RE, Orlowski RZ. Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma. Leukemia. e-Pub 2018. PMID: 29581547.
80. Mohyuddin GR, Faisal MS, Badar T, Shah N, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH. A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. Leuk Lymphoma 59(2):1-4, 2018. e-Pub 2018. PMID: 28673185.
81. Thomas SK, Cha SC, Smith DL, Kim KH, Parshottam SR, Rao S, Popescu M, Lee VY, Neelapu SS, Kwak LW. Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol. BMC Cancer 18(1):187, 2018. e-Pub 2018. PMID: 29439670.
82. Hao S, Lin P, Medeiros LJ, Fang L, Carballo-Zarate AA, Konoplev SN, Sargent RL, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Lu X. Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion. Mod Pathol 30(10):1378-1386, 2017. e-Pub 2017. PMID: 28664940.
83. Mohyuddin GR, Faisal MS, Badar T, Shah N, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH. A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. Leuk Lymphoma 1-4, 2017. e-Pub 2017. PMID: 28673185.
84. Thuro BA, Sagiv O, Shinder R, Debnam JM, Ozgur O, Ng JD, Rootman D, Thomas SK, Esmaeli B. Clinical Presentation and Anatomical Location of Orbital Plasmacytomas. Ophthal Plast Reconstr Surg. e-Pub 2017. PMID: 28582371.
85. Carballo-Zarate AA, Medeiros LJ, Fang L, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Hao S, Shen Q, Orlowski RZ, Lin P, Lu X. Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience. Mod Pathol 30(6):843-853, 2017. e-Pub 2017. PMID: 28281554.
86. Baljevic M, Zaman S, Baladandayuthapani V, Lin YH, de Partovi CM, Berkova Z, Amini B, Thomas SK, Shah JJ, Weber DM, Fu M, Cleeland CS, Wang XS, Stellrecht CM, Davis RE, Gandhi V, Orlowski RZ. Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. Ann Hematol 96(6):977-985, 2017. e-Pub 2017. PMID: 28337527.
87. Bock F, Lu G, Srour SA, Gaballa S, Lin HY, Baladandayuthapani V, Honhar M, Stich M, Shah ND, Bashir Q, Patel K, Popat U, Hosing C, Korbling M, Delgado R, Rondon G, Shah JJ, Thomas SK, Manasanch EE, Isermann B, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 22(12):2159-2164, 2016. e-Pub 2016. PMID: 27638366.
88. Badar T, Cornelison AM, Shah ND, Bashir Q, Parmar S, Patel K, Hosing C, Popat U, Weber DM, Thomas SK, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Systemic Light chain (AL) Amyloidosis with Concurrent Renal and Cardiac Involvement. Eur J Haematol 97(4):342-7, 2016. e-Pub 2016. PMID: 26773409.
89. Cao X, Medeiros LJ, Xia Y, Wang X, Thomas SK, Loghavi S, Li X, Shah JJ, Gustafson SA, Weber DM, Miranda RN, Xu-Monette ZY, Orlowski RZ, Young KH. Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leuk Lymphoma 23(5):1-10, 2016. e-Pub 2016. PMID: 26421453.
90. Zhang XD, Baladandayuthapani V, Lin H, Mulligan G, Li B, Esseltine DL, Qi L, Xu J, Hunziker W, Barlogie B, Usmani SZ, Zhang Q, Crowley J, Hoering A, Shah JJ, Weber DM, Manasanch EE, Thomas SK, Li BZ, Wang HH, Zhang J, Kuiatse I, Tang JL, Wang H, He J, Yang J, Milan E, Cenci S, Ma WC, Wang ZQ, Davis RE, Yang L, Orlowski RZ. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell 29(5):639-52, 2016. e-Pub 2016. PMID: 27132469.
91. Shah JJ, Feng L, Thomas SK, Berkova Z, Weber DM, Wang M, Qazilbash MH, Champlin RE, Mendoza TR, Cleeland C, Orlowski RZ. Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. Blood Cancer J 6:e396, 2016. e-Pub 2016. PMID: 26871714.
92. Jacobs RW, Saliba RM, Sasaki K, Farhan S, Armas A, Shah ND, Bashir Q, Qureshi S, Rondon G, Hosing C, Popat U, Parmar S, Shah JJ, Wang M, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk 16(1):36-42, 2016. e-Pub 2016. PMID: 26702475.
93. Alfaraj WA, Cachia D, Tummala S, Thomas SK, Manasanch EE. Severe peripheral neuropathy following carfilzomib, rituximab, and dexamethasone for initial treatment of Waldenström's macroglobulinemia. Ann Hematol 95(2):347-8, 2016. e-Pub 2016. PMID: 26432713.
94. Mahale P, Thomas SK, Kyvernitakis A, Torres HA. Management of Multiple Myeloma Complicated by Hepatitis C Virus Reactivation: The Role of New Antiviral Therapy. Open Forum Infect Dis 3(1):ofv211, 2016. e-Pub 2016. PMID: 26885541.
95. Mendoza TR, Wang XS, Williams LA, Shi Q, Vichaya EG, Dougherty PM, Thomas SK, Yucel E, Bastida CC, Woodruff JF, Cleeland CS. Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment Scale. J Pain 16(10):1032-43, 2015. e-Pub 2015. PMID: 26210041.
96. Kuiatse I, Baladandayuthapani V, Lin HY, Thomas SK, Bjorklund CC, Weber DM, Wang M, Shah JJ, Zhang XD, Jones RJ, Ansell SM, Yang G, Treon SP, Orlowski RZ. Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy Against Waldenström's Macroglobulinemia. Clin Cancer Res 21(11):2538-45, 2015. e-Pub 2015. PMID: 25748087.
97. Cao X, Ye Q, Orlowski RZ, Wang X, Loghavi S, Tu M, Thomas SK, Shan J, Li S, Qazilbash M, Yin CC, Weber D, Miranda RN, Xu-Monette ZY, Medeiros LJ, Young KH. Waldenstrom macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. J Hematol Oncol 8:74, 2015. e-Pub 2015. PMID: 26104577.
98. Kosturakis AK, He Z, Li Y, Boyette-Davis JA, Shah N, Thomas SK, Zhang H, Vichaya EG, Wang XS, Wendelschafer-Crabb G, Kennedy WR, Simone DA, Cleeland CS, Dougherty PM. Subclinical Peripheral Neuropathy in Patients With Multiple Myeloma Before Chemotherapy Is Correlated With Decreased Fingertip Innervation Density. J Clin Oncol 32(28):3156-62, 2014. e-Pub 2014. PMID: 25154818.
99. Patel K, Nusrat M, Shah N, Bashir Q, Parmar S, Shah J, Thomas S, Weber D, Orlowski RZ, Champlin R, Qazilbash MH. Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome. Bone Marrow Transplant. Bone Marrow Transplant:465-6, 2014. e-Pub 2014.
100. Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M, Weber DM, Orlowski RZ. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia 28(2):373-83, 2014. e-Pub 2014. PMID: 23760401.
101. Thomas SK, Suvorov A, Noens L, Rukavitsin O, Fay J, Wu KL, Zimmerman TM, van de Velde H, Bandekar R, Puchalski TA, Qi M, Uhlar C, Samoylova OS. Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma. Cancer Chemother Pharmacol 73(1):35-42, 2014. e-Pub 2014. PMID: 24149943.
102. Garcia MK, Cohen L, Guo Y, Zhou Y, You B, Chiang J, Orlowski RZ, Weber D, Shah J, Alexanian R, Thomas S, Romaguera J, Zhang L, Badillo M, Chen Y, Wei Q, Lee R, Delasalle K, Green V, Wang M. Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. J Hematol Oncol 7:41, 2014. e-Pub 2014. PMID: 24886772.
103. Vichaya EG, Wang XS, Boyette-Davis JA, Mendoza TR, He Z, Thomas SK, Shah N, Williams LA, Cleeland CS, Dougherty PM. Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy. Cancer Chemother Pharmacol 71(6):1531-40, 2013. e-Pub 2013. PMID: 23543296.
104. Voorhees PM, Manges RF, Sonneveld P, Jagannath S, Somlo G, Krishnan A, Lentzsch S, Frank RC, Zweegman S, Wijermans PW, Orlowski RZ, Kranenburg B, Hall B, Casneuf T, Qin X, van de Velde H, Xie H, Thomas SK. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol 161(3):357-66, 2013. e-Pub 2013. PMID: 23432640.
105. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. e-Pub 2013. PMID: 23545991.
106. Jones D, Vichaya EG, Wang XS, Williams LA, Shah ND, Thomas SK, Johnson VE, Champlin RE, Cleeland CS, Mendoza TR. Validation of the M.S. Anderson sympton inventory multiple myeloma module. J Hematol Oncol 6:13, 2013. e-Pub 2013. PMID: 23384030.
107. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood 120(16):3260-70, 2012. e-Pub 2012. PMID: 22932796.
108. Thomas SK, Kwak LW. Lymphoma Vaccine Therapy: Next Steps After a Positive, Controlled Phase III Clinical Trial. Semin Oncol 39(3):253-62, 2012. e-Pub 2012. PMID: 22595048.
109. Zheng Y, Yang J, Qian J, Zhang L, Lu Y, Li H, Lin H, Lan Y, Liu Z, He J, Hong S, Thomas S, Shah J, Baladandayuthapani V, Kwak LW, Yi Q. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J Mol Med (Berl) 90(6):695-706, 2012. e-Pub 2012. PMID: 22207485.
110. Mendoza TR, Koyyalagunta D, Burton AW, Thomas SK, Phan MH, Giralt SA, Shah JJ, Cleeland CS. Changes in pain and other symptoms in patients with painful multiple myeloma-related vertebral fracture treated with kyphoplasty or vertebroplasty. J Pain 13(6):564-70, 2012. e-Pub 2012. PMID: 22543044.
111. Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 87(3):272-6, 2012. e-Pub 2012. PMID: 22231283.
112. Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Feasibility of autologous hematopoietic stem cell transplant in patients aged 70 years with multiple myeloma. Leuk Lymphoma 53(1):118-22, 2012. e-Pub 2012. PMID: 21780997.
113. Reed V, Shah J, Medeiros LJ, Ha CS, Mazloom A, Weber DM, Arzu IY, Orlowski RZ, Thomas SK, Shihadeh F, Alexanian R, Dabaja BS. Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy. Cancer 117(19):4468-74, 2011. e-Pub 2011. PMID: 21437886.
114. Hunsucker SA, Magarotto V, Kuhn DJ, Kornblau SM, Wang M, Weber DM, Thomas SK, Shah JJ, Voorhees PM, Xie H, Cornfeld M, Nemeth JA, Orlowski RZ. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol 152(5):579-92, 2011. e-Pub 2011. PMID: 21241278.
115. Yang L, Wang H, Kornblau SM, Graber DA, Zhang N, Matthews JA, Wang M, Weber DM, Thomas SK, Shah JJ, Zhang L, Lu G, Zhao M, Muddasani R, Yoo SY, Baggerly KA, Orlowski RZ. Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma. Oncogene 30(11):1329-40, 2011. e-Pub 2011. PMID: 21057542.
116. Ma W, Wang M, Wang ZQ, Sun L, Graber D, Matthews J, Champlin R, Yi Q, Orlowski RZ, Kwak LW, Weber DM, Thomas SK, Shah J, Kornblau S, Davis RE. Effect of Long-term Storage in TRIzol on Microarray-Based Gene Expression Profiling. Cancer Epidemiol Biomarkers Prev 19(10):2445-52, 2010. e-Pub 2010. PMID: 20805315.
117. Wang M, Delasalle K, Feng L, Thomas S, Giralt S, Qazilbash M, Handy B, Lee JJ, Alexanian R. CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplant 45(3):498-504, 2010. e-Pub 2010. PMID: 19633690.
118. Thomas SK, Richards TA, Weber DM. Novel agents for relapsed and/or refractory multiple myeloma. Cancer J 15(6):485-93, 2009. e-Pub 2009. PMID: 20010168.
119. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Körbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 15(6):713-723, 2009. e-Pub 2009. PMID: 19450756.
120. Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GR, Glisson BS, Lee JJ, Herbst RS, Zinner RG. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with Gefitinib on an expanded access program. Clin Lung Cancer 7(5):326-331, 2006. e-Pub 2006. PMID: 16640804.

Invited Articles

1. Thomas SK. Waldenstrom macroglobulinemia – 2020 Update and Future Directions. Clin Lymphoma Myeloma Leuk Suppl 1: S39-S41, 2020. e-Pub 2020.
2. Thomas SK, Kwak LW. Lymphoma Vaccine Therapy: Next Steps After a Positive, Controlled Phase III Clinical Trial. Semin Oncol 39(3):253-62, 2012. e-Pub 2012.
3. Thomas SK, Richards TA, Weber DM. Novel agents for relapsed and/or refractory multiple myeloma. Cancer 15(6):485-93, 2009. e-Pub 2009.
4. Shah JJ, Orlowski RZ, Thomas SK. Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma. Ther Clin Risk Manag 5(1):151-159, 2009. e-Pub 2009. PMID: 19436606.
5. Thomas SK, Richards TA, Weber DM. Lenalidomide in multiple myeloma. Best Pract Res Clin Haematol 20(4)(4):717-735, 2007. e-Pub 2007. PMID: 18070715.
6. Thomas S, Alexanian R. Current treatment strategies for multiple myeloma. Clin Lymphoma Myeloma 7 Suppl 4:S139-44, 2007. e-Pub 2007. PMID: 17562251.
7. Thomas SK. Waldenstrom macroglobulinemia – 2021 Update and Future Directions. Clinical Lymphoma, Myeloma and Leukemia.

Review Articles

1. George M, Mustafayev K, Ahmed S, Thomas SK, Jiang Y, Patel K, Torres HA. Direct-Acting Antivirals Induce Lymphoproliferative Disease Response in HCV-Infected Patients with Indolent B-Cell Non-Hodgkin's Lymphoma: A Prospective Observational Study. Hematol. Oncol, 2025. e-Pub 2025.
2. Damron EP, Qazilbash MH, Fang PQ, Wu SY, Dabaja BS, Rondon G, Hosing C, Champlin RE, Bashir Q, Shpall EJ, Knafl MK, Lee HC, Manasanch EE, Patel K, Thomas SK, Orlowski RZ, Weber DM, Pinnix CC, Gunther JR. Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma. Transplant Cell Ther 29(1):37.e1-37.e7, 2023. e-Pub 2023. PMID: 37753818.
3. Thomas, SK. SOHO State of the Art Updates and Next Questions. Clinical Lymphoma, Myeloma and Leukemia 22(6):347-355, 2022. e-Pub 2022. PMID: 34980578.
4. Dimopoulos MA, Kastritis E, Owen RG, Kyle RA, Landgren O, Morra E, Leleu X, García-Sanz R, Munshi N, Anderson KC, Terpos E, Ghobrial IM, Morel P, Maloney D, Rummel M, Leblond V, Advani RH, Gertz MA, Kyriakou C, Thomas SK, Barlogie B, Gregory SA, Kimby E, Merlini G, Treon SP. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood 124(9):1404-11, 2014. e-Pub 2014. PMID: 25027391.

Professional Educational Materials

1. TS. Waldenstrom Macroglobulinemia MDACC Treatment Algorithm, 2021.
2. Bevers T, Murphy MB, Hume CB, Delucia K, Ferrajoli A, Fleckenstein ON, Oliva IG, Kaseb A, Kovitz C, Martinez A, Miller E, Pai A, Ramirez D, Ratan R, Thomas SK, Tummala S. Hepatitis B MDACC Screen and Management Algorithm, 2021.
3. SK T. Multiple Myeloma Treatment Algorithm. M.D. Anderson Cancer Center, 2017.
4. Thomas S. Multiple Myeloma: Questions and Answers. M.D. Anderson Cancer Center, 2005.

Other Articles

1. Chohan KL, Gensini L, Seif S, Sun X, Feng L, Becnel MR, Gaballa MM, Lee HC, Pasvolsky O, Patel KK, Ye J, Weber DM, Orlowski RZ, Thomas SK Long-Term Outcomes in Waldenström Macroglobulinemia (Wm) Patients Who Discontinue Bruton's Tyrosine Kinase Inhibitor (Btki) Therapy 15(211), 2025.

Abstracts

1. Ebrahimi S, Shah N, Nakamatsu N, Vakilpour A, Lu E, Triantafyllou E, Goyal A, Seif SM, Gensini L, Thomas SK, Randazzo M, Kumar S, Hamzeh I, Kaufman M, Patel M, Singulane C, Scherrer-Crosbie M, Cheng R, Asch F, Deswal A, Slivnick J, Koutroumpakis E. AI-Derived Multiparametric Scores for the Diagnosis of Cardiac Involvement in Patients with AL Amyloidosis. 2026 Annual Meeting of the American College of Cardiology. e-Pub 2026.
2. Thomas SK, Manasanch E, Jagannath S, Korde N, Lee H, Berrios D, Patel K, Iyer S, Mailankody S, Amini B, Lin P, Berkova Z, Weber D, Kaufman G, Feng L, Hildebrandt M, Wang L, Neelapu S, Orlowski R, Landgren O. Final results of a multi-center phase 2 trial of isatuximab-lenalidomide in patients with high risk smoldering multiple myeloma (HRSMM). ASH, 2025. e-Pub 2025.
3. Pasvolsky O, Milton DR, Tanner MR, Bashir Q, Srour SA, Saini NY, Lin P, Patel A, Khan HN, Ramdial J, Nieto Y, Tang G, Haider A, Aljawai YM, Ahmed S, Kebriaei P, Lee HC, Ye C, Patel KK, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant. ASH, 2025. e-Pub 2025.
4. Pasvolsky O, Milton D, Rafaeli N, Tanner M, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Mohamedi A, Aljawai Y, Lee H, Patel K, Kebriaei P, Thomas SK, Orlowski R, Shpall E, Champlin R, Qazilbash M. Outcomes of Multiple Myeloma Patients With Prior Solid Tumors Undergoing an Autologous Transplant. International Myeloma Society, 2025. e-Pub 2025.
5. Chohan K, Gensini L, Seif S, Sun X, Feng L, Sanchez J, Becnel MR, Gaballa M, Lee H, Pasvolsky O, Patel K, Ye JC, Weber D, Orlowski RZ, Thomas SK. Long-term outcomes in Waldenström macroglobulinemia (WM) patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy. ICML, 2025. e-Pub 2025.
6. Chohan K, Gensini L, Seif S, Sun X, Feng L, Sanchez J, Becnel MR, Gaballa M, Lee H, Pasvolsky O, Patel K, Ye JC, Weber D, Orlowski RZ, Thomas SK. Long-term outcomes in Waldenström macroglobulinemia (WM) patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy. EHA 2025, 2025. e-Pub 2025.
7. George M, Mustafayev K, Ahmed S, Thomas SK, Jiang Y, Patel K, Torres HA. Direct-Acting Antivirals Induce Lymphoproliferative Disease Response in HCV-Infected Patients With Indolent B-Cell Non-Hodgkin’s Lymphoma: A Prospective Observational Study 43(2):e70044, 2025. e-Pub 2025. PMID: 39921915.
8. Seif S, Lionel A, Sun X, Feng L, Gensini L, Sanchez J, Bansal H, Becnel M, Gaballa M, Lee H, Pasvolsky O, Patel K, Ye J, Patel K, Weber D, Orlowski R, Thomas SK. Impact of TP53 mutation status on cancer-specific survival after first-line treatment in lymphoplasmacytic lymphoma. EHA, 2025. e-Pub 2025.
9. Chohan K, Gensini L, Seif S, Sun X, Feng L, Sanchez J, Becnel MR, Gaballa MR, Lee HC, Pasvolsky O, Patel KK, Ye J, Weber DM, Orlowski R, Thomas SK. Long-term outcomes in Waldenstrom macroglobulinemia (WM) patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy. ASCO, 2025. e-Pub 2025.
10. Jetty S, Makhoul J, Khawaja F, Patel K, Lee HC, Thomas SK, Gensini L, Seif S, de Partovi CM, Horowitz S, Spallone A, Heredia EA, Chemaly RF. Infectious complications in patients with relapsed and refractory multiple myeloma undergoing novel bispecific antibody therapy. European Society of
 Clinical Microbiology and Infectious Diseases, 2025. e-Pub 2025.
11. Makhoul J, Jetty S, Khawaja F, Patel K, Lee H, Thomas SK, Gensini L, Partovi C, Seif S, Horowitz S, Spallone A, Heredia E, Chemaly RF. Cytomegalovirus infections in patients with relapsed/refractory multiple myeloma on novel therapies. European Society of
 Clinical Microbiology and Infectious Diseases, 2025. e-Pub 2025.
12. Dang M, Lee HC, Bansal H, Acevedo-Calado M, Qin L, Tan W, Moreno Rueda LY, Berrios D, Patel KK, Lin P, Thomas SK, Weber DM, Wang L, Orlowski RZ. Single-Cell Multi-Omic Profiling of Patients with BCMA-Targeted Therapy Identifies Molecular and Cellular Factors Associated with Responsiveness and Treatment Effects. ASH, 2024. e-Pub 2024.
13. Ailawadhi S, Gavriatopoulou M, Peterson J, Ntanasis-Stathopoulos I, El-Haddad G, Grajales-Cruz A, Afrough A, Levy MY, Trotman J, Doucette KR, Castillo JJ, Hernandez-Ilizaliturri F, Nooka AK, D'Sa S, Boccia RV, Parmar H, de Larrea CF, Seval GC, Goncalves Beber LB, Ramchandren R, Thomas SK, Longcor J, Shustov A. Iopofosine I 131 in Previously Treated Patients with Waldenstrom Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM). ASH, 2024. e-Pub 2024.
14. Cervoni Curet FN, Bassett RL, Pasvolsky O, Deen AF, Tanner MR, Bashir Q, Srour SA, Saini NY, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Fingrut WB, Smallbone P, Becnel MR, Gaballa MR, Thomas SK, Ye J, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma. ASH, 2024. e-Pub 2024.
15. Dhakal B, Slade M, Narra R, Mohamed ME, Akhtar OS, Bansal H, Acevedo-Calado MJ, Pasvolsky O, Gaballa MR, Becnel MR, Weber DM, Patel KK, Thomas SK, Ye J, Kuhr F, Dong B, Powell S, Bui T, Mohan M, Pasquini MC, D'Souza A, Knysh H, Orlowski RZ, Albitar M, Lee HC. Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma. ASH, 2024. e-Pub 2024.
16. Dang M, Seif S, Acevedo-Calado MJ, Wang L, Gabriel B, Lewis LS, Gensini L, Bansal H, Becnel MR, Gaballa MR, Lee HC, Pasvolsky O, Patel KK, Weber DM, Ye J, Orlowski RZ, PhD, Thomas SK. Characterization of WM/LPL Using Single Cell Transcriptomic Analysis. ASH, 2024. e-Pub 2024.
17. Sami SS, Bashir Q, Saini NY, Aljawai YM, Hosing C, Popat U, Becnel MR, Kaufman GP, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Srour SA. Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis. ASH, 2024. e-Pub 2024.
18. Deen AF, Bashir Q, Saini NY, Aljawai YM, Hosing C, Popat U, Becnel MR, Kaufman GP, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Srour SA. Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis. ASH, 2024. e-Pub 2024.
19. Ye J, Tang G, Pasvolsky O, Becnel MR, Gaballa MR, Patel KK, Lee HC, Thomas SK, Weber DM, Lin P, Orlowski RZ. Unveiling Clinical Potential: Exploring Cytogenomic Aberrations through Optical Genomic Mapping in Multiple Myeloma. ASH, 2024. e-Pub 2024.
20. Dillard CM, Gurumurthi A, Lee HC, Thomas SK, Weber DM, Orlowski RZ, Qazilbash MH, Patel KK, Hildebrandt MA. Association of Social Determinants of Health Status (SDOH) and Ethnicity with Survival in Multiple Myeloma Patients. ASH, 2024. e-Pub 2024.
21. Patel KK, Manasanch EE, Lee HC, Ye J, Thomas SK, Weber DM, Becnel MR, Gaballa MR, Bansal H, Berkova Z, Neelapu SS, Haymaker CL, Dang M, Wang L, Lizee G, Orlowski RZ. Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM). ASH, 2024. e-Pub 2024.
22. Low R, Warden A, Postek M, Denardis P, Kyriakou C, Olszewski AJ, Kersten MJ, Vos JM, Thomas SK, D'Sa S, Guerin N, Harrington C, Trotman J, Tohidi-Esfahan I. Real World Treatment Outcomes in the First Line Management of Waldenström Macroglobulinemia from the Global Patient Derived Data Registry, Whimsical. ASH, 2024. e-Pub 2024.
23. Dang M, Seif S, Acevedo-Calado MJ, Wang L, Gabriel B, Lewis LS, Gensini L, Bansal H, Becnel MR, Gaballa MR, Lee HC, Pasvolsky O, Patel KK, Weber DM, MD, Ye J, Orlowski RZ, Thomas SK. Characterization of Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma Using Single Cell Transcriptomic Analysis. ASH, 2024. e-Pub 2024.
24. Lionel A, Seif S, Sun X, Feng L, Gensini L, Gabriel B, Lewis LS, Bansal H, Becnel MR, Gaballa MR, Lee HC, Pasvolsky O, Patel KK, Ye J, Patel KP, Weber DM, Orlowski RZ, Thomas SK. Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma. ASH, 2024. e-Pub 2024.
25. Richter J, Thomas SK, Krishnan AY, Laubach JP, Cohen AD, Trudel S, Costa LJ, Bahlis NJ, Forsberg PA, Kaedbey R, Fonseca R, Spencer A, Rodríguez-Otero P, Mateos M, Wong C, Cooper J, Tyagi T, Nakamura R, Choeurng V, Lesokhin AM. Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies. ASH, 2024. e-Pub 2024.
26. Dang M, Lee HC, Bansal H, Acevedo-Calado MJ, Qin L, Tan W, Moreno Rueda LY, Berrios D, Pasvolsky O, Gaballa MR, Becnel MR, Ye J, Patel KK, Lin P, Thomas SK, Weber DM, Wang L, Orlowski RZ. Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma. ASH, 2024. e-Pub 2024.
27. Dang M, Seif S, Acevedo-Calado MJ, Wang L, Gabriel B, Lewis LS, Gensini L, Bansal H, Becnel MR, Gaballa MR, Lee HC, Pasvolsky O, Patel KK, Weber DM, Ye J, Orlowski RZ, Thomas SK. Characterization of WM/LPL Using Single Cell Transcriptomic Analysis. 12th International Workshop on Waldenstrom’s Macroglobulinemia (IWWM12), 2024. e-Pub 2024.
28. Marcoux C, Pasyar S, Milton D, Khan H, Tanner M, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Neupane N, Lee H, Patel K, Tang G, Lee J, Aljawai Y, Kebriaei P, Thomas SK, Orlowski R, Shpall E, Champlin R, Qazilbash M, Pasvolsky O. Impact of Obesity on Outcomes of Multiple Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant. International Myeloma Society, 2024. e-Pub 2024.
29. Pasvolsky O, Wang Z, Milton D, Pal B, Tanner M, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Syed N, Aljawai Y, Lee H, Patel K, Kebriaei P, Thomas SK, Orlowski R, Shpall E, Champlin R, Qazilbash M. Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation. International Myeloma Society, 2024. e-Pub 2024.
30. Thomas SK, Manasanch E, Korde N, Lee H, Jagannath S, Becnel M, Kaufman G, Patel K, Iyer S, Mailankody S, Weber D, Lutter-Berka Z, Carpenter S, Nolasco DB, Hildebrandt M, Feng L, Amini B, Neelapu S, Orlowski R, Landgren O. Interim Results of a Phase 2 Trial of Isatuximab-Lenalidomide for Patients with High-Risk Smoldering Multiple Myeloma. International Myeloma Society, 2024. e-Pub 2024.
31. Dillard C, Hildebrandt M, Lee H, Kalariya N, Subramanian N, Pasvolsky O, Ferreri C, Gaballa M, Thomas SK, Weber D, Becnel M, Kaufman G, Chen J, Hawkins M, Abreu M, Qazilbash M, Orlowski R, Patel K. Impact of Genetic Ancestry on Outcomes and Toxicity of Idecel in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM). International Myeloma Society, 2024. e-Pub 2024.
32. Lu R, Chen J, Ow K, Hildebrandt M, Huen A, Cardoso R, Chambers M, Abreu M, Cuellar E, Ighovoyivwi E, Knight S, Santiago M, Savoie C, Varghese J, Zachariah A, Becnel M, Gaballa M, Orlowski R, Patel K, Pasvolsky O, Thomas SK, Ye JC, Weber D, Lee H, Richards T. Evaluation of Clinical Outcomes and Toxicities in Multiple Myeloma Patients Receiving Commercial Talquetamab. International Myeloma Society, 2024. e-Pub 2024.
33. Pasvolsky O, Marcoux C, Dai J, Milton DR, Tanner MR, Syed PN, Bashir Q, Srour SA, Saini NY, Lin P, Ramdial J, Nieto Y, Lee H, Patel KK, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Trends in Outcomes over Three Decades after Upfront Autologous Stem Cell Transplant for Multiple Myeloma at MD Anderson Cancer Center. ASH, 2024. e-Pub 2024. PMID: 38852784.
34. Thomas SK, George JS, de Partovi CMM, Feng L, Morphey AS, Becnel MR, Kaufman GP, Lee HC, Manasanch EE, Patel KK, Pasvolsky O, Ye JC, Amini B, Qazilbash MH, Bashir Q, Crumpton BN, Stafford MM, Ralph J Johnson III, Weber DM, Orlowski RZ. Final results of a phase II study of lenalidomide-elotuzumab as maintenance therapy post-autologous stem cell transplant (AuSCT) in patients (Pts) with multiple myeloma (MM). ASCO 2024, 2024. e-Pub 2024.
35. Pasvolsky O, Ghanem S, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour SA, Saini NY, Lin P, Ramdial J, Nieto Y, Khan HN, Kebriaei P, Lee H, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, H Qazilbash AM. Outcomes of Patients with Multiple Myeloma and 1q Gain/Amplification Receiving Autologous Hematopoietic Stem Cell Transplant: The MD Anderson Cancer Center Experience. ASH, 2024. e-Pub 2024. PMID: 38199987.
36. Aljawai Y, Pasvolsky O, Patel K, Bashir Q, Sui D, Srour S, Tanner M, Popat U, Saini N, Hosing C, Ramdial J, Lee H, Kaufman G, Thomas SK, Weber D, Becnel M, Tang G, Orlowski R, Patel D, Champlin R, Nieto Y, Shpall E, Qazilbash M. Daratumumab Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hematopoietic Stem Cell Transplantation. International Myeloma Society, 2023. e-Pub 2023.
37. Bashir Q, Thall P, Sui D, Kawedia J, Knape C, Delgado R, Schindler JL, Popat UR, Kebriaei P, Hosing C, Khouri IF, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Alatrash G, Rondon G, Lee H, Thomas SK, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Shpall EJ, H Qazilbash AM. Phase 1/2 Trial to Jointly Optimize Dose and Administration Schedule of Evomela in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. ASH, 2023. e-Pub 2023.
38. Mustafayev K, Arvelaez J, Naing A, Thomas SK, Patel KK, Pemmaraju V, Daver NG, Jiang Y, Yepez Guevara E, Torres HA. The Use of Direct-Acting Antivirals to Enhance Access to Cancer Clinical Trials for Patients with Chronic Hepatitis C Virus Infection and Cancer. The Liver Meeting, 2023. e-Pub 2023.
39. Chiu CY, Ahmed S, Thomas SK, Wang LS, Mustafayev K, Fayad LE, Wierda WG, Khawaja F, Torres HA. Hepatitis B virus reactivation in patients receiving Bruton tyrosine kinase inhibitors. Clinical Lymphoma Myeloma Leuk, 2023. e-Pub 2023.
40. Trudel S, Cohen AD, Krishnan AY, Fonseca R, Spencer A, Berdeja JG, Lesokhin A, Forsberg PA, Laubach JP, Costa LJ, Rodriguez-Otero P, Kaedbey R, Richter J, M-V M, Thomas SK, Wong C, Li M, Choeurng V, Vaze A, Samineni D, Sumiyoshi T, Cooper J, Harrison SJ. Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study. Blood 138(653):157, 2021. e-Pub 2021.
41. Tohidi-Esfahani I, Warden A, Malunis E, deNardis PL, Postek M, D'Sa S, Kersten MJ, Thomas SK, Palomba ML, Olszewski AJ, Guerin N, Scott C, and Trotman J. Global Waldenström’s Macroglobulinemia Patient-Derived Data Registry, Whimsical, Highlights Real-World Treatment Outcomes and COVID-19 Data. Blood 138(623):1343, 2021. e-Pub 2021.
42. Treon SP, Buske C, Thomas SK, Castillo JJ, Branagan AR, Dimopoulos MA, Gavriatopoulou M, Cadavid D, Garzon FT, Tang W, Seyffert S, Garg V, Ali S, Taveras AG, Chen K, Matous JV. Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström’s Macroglobulinemia With MYD88 and CXCR4 Mutations. Blood 138(623):1343, 2021. e-Pub 2021.
43. Bashir Q, Thall PF, Sui D, Ramdial JL, Srour SA, Mehta RS, Popat UR, Nieto Y, Saini N, Kebriaei P, Manasanch EE, Lee HC, Kaufman GP, Thomas SK, Patel KK, Orlowski RZ, Knape CG, Kawedia JD, Champlin RE, Shpall EJ, Liu X, Qazilbash MH. A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule and Dose of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma. Blood 138(731):3941, 2021. e-Pub 2021.
44. Shank BR, Primeaux B, Horowitz SB, Yeung EK, Lee IY, Kaufman GP, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Weber DM, Thomas SK. Daratumumab (Dara) and hyperfractionated cyclophosphamide (HyperCy)/dexamethasone (Dex) with and without carfilzomib (Car) for the treatment of relapsed/refractory multiple myeloma (RRMM). J Clin Oncol 38(Suppl), 2020. e-Pub 2020.
45. Afrough A, Alsfeld LC, Delgado R, Popat UR, Kebriaei P, Oran B, Saini N, Srour SA, Hosing C, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Orlowski RZ, Pinnix CC, Dabaja BS, Thomas SK, Weber DM, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Blood 136(Suppl 1):22, 2020. e-Pub 2020.
46. Saini N, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing C, Nieto Y, Kebriaei P, Alousi AM, Mehta RS, Srour SA, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. African-Americans Multiple-Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Have Similar Survival Outcomes Compared to Whites: A Propensity-Score Matched Analysis. Blood 136(Suppl 1):9-10, 2020. e-Pub 2020.
47. Manasanch EE, Han G, Zhang Z, Dang M, Singh M, Khan M, Singh S, Lee HC, Patel KK, Kaufman GP, Amini B, Bashir Q, Srour SA, Nieto Y, Qazilbash MH, Berkova, Z, Lin P, Berry D, Thomas SK, Weber DM, Futreal PA, Wang L, Orlowski RZ, Neelapu SS. Extensive Changes of the Immune Microenvironment Are Associated with Progression from Precursor Stages to Multiple Myeloma. Blood 136(Suppl 1):37-38, 2020. e-Pub 2020.
48. Ramdial JL, Gaballa MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini N, Nieto Y, Hosing C, Popat UR, Murphy R, Lee HC, Patel KK, Manasanch EE, Thomas SK, Weber DM, Kaufman GP, Orlowski RZ, Champlin RE, Qazilbash MH. Outcomes in Patients with AL (Light-Chain) Cardiac Amyloidosis. Blood 136(Suppl 1):11-13, 2020. e-Pub 2020.
49. Yeung EK, Primeaux BR, Horowitz SB, Shank BR, Lee IY, Kaufamn GP, Lee HC, Manasanch EE, Patel KK, Orlwoski RZ, Dm W, Thomas SK. Hyperfractionated Cyclophosphamide-Dexamethasone (HyperCy-Dex) with or without Carfilzomib (Car) in Patients (pts) with Multiple Myeloma (MM). Blood 136(Suppl 1):19-20, 2020. e-Pub 2020.
50. Afrough A, Srour SA, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Shpall EJ, Delgado R, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Prognostic Impact of Beta 2 Microglobulin in Patients with Immunoglobulin Light-Chain Amyloidosis Undergoing Autologous Hematopoietic Stem Cell Transplantation. Blood 136(Suppl 1):20-21, 2020. e-Pub 2020.
51. Becnel MR, Horowitz SB, Thomas SK, Iyer SP, Patel KK, Manasanch EE, Weber DM, Kaufman GP, Lee HC, Orlowski RZ. Descriptive Analysis of Isatuximab Use Following Prior Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma. Blood 136(Suppl 1):20-21, 2020. e-Pub 2020.
52. Ramdial JL, Ma J, Milton D, Delgado R, Bashir Q, Srour SA, Saini N, Nieto Y, Hosing C, Popat UR, Murphy R, Lee HC, Patel KK, Manasanch EE, Thomas SK, Kaufman GP, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. PBSC Mobilization for Auto-HSCT in Myeloma: Growth Factors Vs Growth Factors + Chemotherapy. Blood 136(Suppl 1):6-7, 2020. e-Pub 2020.
53. Afrough A, Alsfeld LC, Srour SA, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Shpall EJ, Delgado R, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with t(11;14) Undergoing Autologous Hematopoietic Stem Cell Transplantation. Blood 136(Suppl 1):18-19, 2020. e-Pub 2020.
54. Thomas SK, Cha S, Parshottam SR, Rao SS, Olsem JB, Crumpton BN, Szymura S, Wang Z, Anderson A, Feng L, Lee HC, Manasanch EE, Patel KK, Weber DM, Orlowski RZ, Neelapu SS, Kwak LW. A Novel Therapeutic DNA Vaccine Elicits Reduction of Tumor Clones and Favorable Perturbations in the Immune Microenvironment in Patients (pts) with Untreated Smoldering Waldenström Macroglobulinemia (sWM). Blood 136(Suppl 1):6-7, 2020. e-Pub 2020.
55. Thomas SK, Shah JJ, Morin A, Morphey AN, Lee HC, Manasanch EE, Patel KK, Kaufman GP, Iyer SP, Feng L, Amini B, Qazilbash MH, Bashir Q, Saini N, Srour SA, Johnson RJ, Crumptom BN, Stafford MD, Weber DM, Orlowski RZ. Update of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM). Blood 136(Suppl 1):46-47, 2020. e-Pub 2020.
56. Gaballa MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini N, Ramdial JL, Nieto Y, Murphy R, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Outcomes of Patients with Multiple Myeloma Who Received VRD Induction, Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance. Blood 136(Suppl 1):14-15, 2020. e-Pub 2020.
57. Patel K, J-M M, Chanan-Khan AA, Salles GA, Cartron G, Peyrade F, Bouabdullah R, Reid EG, et al TS. Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. Blood 134 (1):4079, 2019. e-Pub 2019.
58. Kunacheewa C, Feng L, Manasanch EE, Bashir Q, Patel KK, Mehta RS, Kaufman GP, Iyer SP, Thomas SK, Weber DM, Orlowski RZ, Qazilbash MH, Lee HC. Outcomes of Lenalidomide Retreatment with Novel Triplet Regimens in Multiple Myeloma Patients Progressing on Lenalidomide-Based Maintenance Therapy: A Single Center Retrospective Analysis. Blood 134 (1):3198, 2019. e-Pub 2019.
59. Manasanch EE, Jagannath S, Lee HC, Patel KK, Graham C, Kaufman GP, Thomas SK, Iyer SP, Mailankody S, Korde N, Amini B, Lin P, Berkova Z, Weber DM, Feng L, Lendvai N, Hildebrandt M, Neelapu SS, Orlowski RZ, Landgren O. A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM). Blood 134 (1):3116, 2019. e-Pub 2019.
60. Kunacheewa C, Patel KK, Lee HC, Thomas SK, Amini B, Srour S, Bashir Q, Qazilbash MH, Weber DM, Neelapu SS, Orlowski RZ, Feng L, Lin P, Manasanch EE. Correlation of minimal residual disease negativity (MRD-) with prognosis in high-risk myeloma (HRM). Journal of Clinical Oncology 37:8024, 2019. e-Pub 2019.
61. Thomas SK, Cha S, Parshottam SR, Rao SS, Olsem JB, Crumpton BN, Feng L, Lee HC, Manasanch EE, Weber DM, Patel KK, Orlowski RZ, Neelapu SS, Kwak LW. Phase I trial of a novel DNA vaccine in patients (pts) with smoldering Waldenstrom macroglobulinemia (sWM). Journal of Clinical Oncology 37:8050, 2019. e-Pub 2019.
62. Qazilbash M, Thall P, Milton D, Kawedia J, Saini N, Kebriaei P, Patel K, Andersson B, Nieto Y, Valdez B, Rondon G, Delgado R, Hosing C, Popat U, Lin P, Thomas SK, Lee H, Orlowski R, Champlin R, Shpall E, Bashir Q. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. International Myeloma Society, 2019. e-Pub 2019.
63. DMCD S, Saliba RM, Patel RO, Bashir QA, Hosing CH, Kebriaei PA, Khouri IF, Nieto YA, Popat UD, Lee HC, Manasanch EE, Patel KK, SK T, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Older Age As a Prognostic Factor for Overall Survival for Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Blood Journal 132, 2018. e-Pub 2018.
64. SK T, Shah JJ, Morphey AN, Lee HC, Manasanch EE, Patel KK, Miller CP, Phillips S, Crumpton BN, Johnson RJ, Feng LE, Iyer SW, Behrang A, Weber DM, Orlowski RZ. Updated Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM). Blood Journal 132, 2018. e-Pub 2018.
65. Saini NY, Patel RO, Varma AN, Bashir QA, Hasan OM, Delgado RU, Rondon GA, Mukherjee AK, Popat UD, Hosing CH, Nieto YA, Kebriaei PA, Weber DM, SK T, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Long-Term Durable Responses after Autologous Stem Cell Transplantation in POEMS Syndrome. Blood Journal 132, 2018. e-Pub 2018.
66. Varma AN, Saini NY, Sui DA, Milton DR, Hasan OM, Mukherjee AK, Bashir QA, Rondon GA, Srour SA, Popat UD, Hosing CH, Nieto YA, Kebriaei PA, Alousi AM, Mehta RS, Khouri IF, Weber DM, SK T, Manasanch EE, Lee HC, Patel KK, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation. Blood Journal 132, 2018. e-Pub 2018.
67. Patel RO, Saini NY, Varma AN, Hasan OM, Bashir QA, Delgado RU, Popat UD, Hosing CH, Mukherjee AK, Nieto YA, Kebriaei PA, Weber DM, SK T, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Outcome of Autologous Stem Cell Transplantation in Waldenström's Macroglobulinemia. Blood Journal 132, 2018. e-Pub 2018.
68. Saini NY, Patel RO, Varma AN, Bashir QA, Hasan OM, Delgado RU, Rondon GA, Mukherjee AK, Popat UD, Hosing CH, Nieto YA, Kebriaei PA, Weber DM, SK T, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Long-Term Durable Responses after Autologous Stem Cell Transplantation in POEMS Syndrome. Blood Journal 132, 2018. e-Pub 2018.
69. Saini NY, Varma AN, Ma JU, Milton DR, Patel RO, Hasan OM, Bashir QA, Nieto YA, Mukherjee AK, Delgado RU, Rondon GA, Popat UD, Hosing CH, Kebriaei PA, Alousi AM, Ahmed SA, Mehta RS, Ciurea SO, Khouri IF, Shpall EJ, Weber DM, SK T, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of t(11;14) on the Outcome of Autologous Transplantation in Multiple Myeloma: A Matched-Pair Analysis. Blood Journal 132, 2018. e-Pub 2018.
70. Saini NY, Patel RO, Varma AN, Bashir QA, Delgado RU, Popat UD, Hosing CH, Nieto YA, Kebriaei PA, Alousi AM, Ahmed SA, Mukherjee AK, Mehta RS, Khouri IF, Ciurea SO, Shpall EJ, Omar H, Weber DM, SK T, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan-Based Autologous Transplantation in the Octogenarian Multiple Myeloma Patient Population. Blood Journal 132, 2018. e-Pub 2018.
71. Becnel MR, Rubin ML, Nair RA, Manasanch EE, Lee HC, Patel KK, Iyer S, SK T, Weber DM, Orlowski RZ. Effect of Timing of Monoclonal Antibody Therapy on the Time to Next Treatment and Response Rate in Heavily Pre-Treated Patients with Myeloma Who Separately Received Both Daratumumab and Elotuzumab-Based Regimens. Blood Journal 132, 2018. e-Pub 2018.
72. Owen R, McCarthy H, Rule S, D'Sa S, TS. Acalabrutinib in Waldenstrom Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia 18 (1):S285–S286, 2018. e-Pub 2018.
73. Aboudalle IM, Khan MA, Feng LE, SK T, Manasanch EE, Patel KK, Medeiros JE, Mehta RO, Bashir Q, Qazilbash MH, Orlowski RZ, Weber DM, Hu SH, Lee HC. Characteristics and outcomes of primary plasma cell leukemia in the era of novel agents: Single center experience. J Clin Oncol 36, 2018. e-Pub 2018.
74. Owen RO, McCarthy H, Rule SI, D’Sa SH, SK T, Forconi FR, Anderson TC, Kersten MJ, Zinzani PL, Iyengar SU, Kothari JA, Minnema MO, Kastritis EF, Izumi RA, Slatter GR, Mittag DI, Wei H, Chen DI, Patel PR, Furman RR. Acalabrutinib in patients (pts) with Waldenström macroglobulinemia (WM). J Clin Oncol 36, 2018. e-Pub 2018.
75. Hildebrandt MAT, Callender RA, Belachew AA, Classen CA, Lee HC, KK P, Richards TA, Thomas SK, Weber DM, Orlowski RZ, Manasanch EE. Quality of life and cancer worry in a follow-up cohort of patients with asymptomatic monoclonal gammopathies. J Clin Oncol 36, 2018. e-Pub 2018.
76. Tabchi SA, Nair RA, Patel KK, Lee HC, SK T, Amini BE, Ahmed SA, Mehta RS, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ, Alexanian RA, Feng LE, Manasanch EE. The MD Anderson modified cyclophosphamide, bortezomib, doxorubicin, and dexamethasone (mCBAD) for the treatment of newly diagnosed (NDMM) and relapsed/refractory multiple myeloma (RRMM). J Clin Oncol 36, 2018. e-Pub 2018.
77. Owen R, McCarthy H, Rule S, D'Sa S, TS. ACALABRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA. European Hematology Association 23 Annual Meeting Abstracts:S853, 2018. e-Pub 2018.
78. Cordas Dos Santos DM, Saliba RM, Patel R, Bashir Q, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Popat U, Lee HC, Manasanch EE, Patel KK, SK T, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Older Age As a Prognostic Factor for Overall Survival for Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Blood 2018 132(2144), 2018. e-Pub 2018.
79. SK T, Shah JJ, Lee HC, Manasanch EE, Weber DM, Patel KK, Feng LE, Amini BE, Morphey A, Crumpton BR, Phillips SA, Miller CA, Gonzalez MA, Orlowski RZ. Preliminary Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood Journal 130(Suppl 1), 2017. e-Pub 2017.
80. Mathur RO, Zhang ZH, He JI, Galetto RO, Gouble AG, Sotinel IC, Filipe ST, Gariboldi AN, Veeramachaneni TA, Manasanch EE, SK T, Lee HC, Patel KK, Weber DM, Davis RE, Orlowski RJ, Smith JU, Yang JI, Neelapu SS. Universal SLAMF7-Specific CAR T-Cells As Treatment for Multiple Myeloma. Blood Journal 130(Suppl 1), 2017. e-Pub 2017.
81. Qazilbash MH, Stadtmauer EA, Baladandayuthapani VE, Lin HE, Tross BE, Honhar ME, Cha SC, Kim KU, Popescu MI, Shah NI, Bashir QA, Patel KK, Lee VY, Shpall EJ, Weber DM, SK T, Orlowski RZ, Kerr NA, Garfall AL, Cohen AD, Vogl DT, Dengel KA, June CH, Champlin RE, Kwak LW. Randomized Phase II Trial of Combination Idiotype Vaccine and Adoptive Cell Transfer of Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation. Blood Journal 130(Suppl 1), 2017. e-Pub 2017.
82. Esfahani IT, Warden A, DeNardis PE, Malunis EL, D’Sa SH, Kersten MJ, Palomba ML, Spearing RU, Ysebaert LO, SK T, Tam CS, Scott CL, Harrington CA, Trotman JU. Whimsical (Waldenström's Macroglobulinemia Study Involving CArt-wheeL): Empowering Patients Internationally to Contribute Patient-Derived Data for Observational Research. Blood Journal 130(Suppl 1), 2017. e-Pub 2017.
83. Manasanch EE, Claussen CM, Dong WE, Lee HC, SK T, Patel KK, Reed VK, Dabaja BS, Milgrom S, Pinnix CC, Parmar SI, Bashir QA, Qazilbash MH, Amini BE, Rayomond AL, Orlowski RZ, Feng LE, Weber DM. A Clinical Model of Progression to Multiple Myeloma in Solitary Plasmacytoma. Blood Journal 130(Suppl 1), 2017. e-Pub 2017.
84. Chaudhry M, Steiner RA, Claussen CM, Patel KK, Lee HC, Weber DM, SK T, Feng CH, Kramer M, Amini BE, Orlowski RZ, Feng LE, Manasanch EE. Carfilzomib-Based Combination Regimens Are Highly Effective Frontline Therapies for Multiple Myeloma and Waldenström's Macroglobulinemia. Blood Journal 130(Suppl 1), 2017. e-Pub 2017.
85. Manasanch EE, Mathur RO, Lee HC, Weber DM, Patel KK, SK T, Munoz SC, Partovi CMD, Claussen CM, Lin PE, Amini BE, Wang LI, Ma MCJ, Qing YU, Lei FE, Baladandayuthapani VE, Davis ER, Neelapuand SS, Orlowski RZ. Pilot Study of Pembrolizumab for Immunoprevention in Smoldering Multiple Myeloma. Blood Journal 130(Suppl 1), 2017. e-Pub 2017.
86. Mathur RO, Barnett BE, Hermanson DA, He J, Zhang ZH, Rengarajan SR, Codde RE, Wang XI, Tan YE, Martin CH, Smith JE, Lee HC, Manasanch EE, SK T, Patel KK, Weber DM, Davis E, Orlowski RZ, Ostertag EM, Shedlock DE, Ji Y, Neelapu SS. B-Cell Maturation Antigen (BCMA)-Specific, CentyrinTM-Based, PiggyBacTM-Transposed CAR-T Memory Stem Cells Are Effective Against p53-/- and Patient-Derived Multiple Myeloma Tumors. Blood Journal 130(Suppl 1), 2017. e-Pub 2017.
87. Claussen CM, Chuang TA, Chaudhry MA, Lee HC, Patel KK, Bashir QA, Parmar SI, Ahmed SA, Mehta RS, SK T, Richards TA, Nieto YA, Shpall EJ, Qazilbash MH, Amini BE, Davis RE, Neelapu SS, Weber DM, Orlowski RZ, Feng LE, Manasanch EE. Gene Expression Profiling Is a Strong Predictor of Clinical Outcomes in Newly Diagnosed Multiple Myeloma. Blood Journal 130(Suppl 1), 2017. e-Pub 2017.
88. Manasanch EE, Lee HC, Patel KK, Weber DM, Lee HJ, SK T, Chen W, On O, Badillo M, Graham V, Lei FE, McCarthy MS, Orlowski RZ, Wang M. A Phase I/II Study of Pomalidomide and Dexamethasone with Growth Factor Support in Patients with Relapsed/Refractory Multiple Myeloma. Blood Journal 130(Suppl 1), 2017. e-Pub 2017.
89. Qazilbash MH, Bashir QA, Thall PF, Milton DR, Shah NI, Patel KK, Andersson BS, Nieto YA, Kebriaei PA, Valdez BC, Kawedia JI, Parmar SI, Delgado RU, Thomas SK, Manasanch EE, Lee HC, Orlowski RZ, Champlin RE. A Randomized Phase III Trial of Busulfan + Melphalan Vs Melphalan Alone for Multiple Myeloma. Blood Journal 130(Suppl 1), 2017. e-Pub 2017.
90. Patel KK, Shah JJ, Feng LE, Lee HC, Manasanch EE, SK T, Weber DM, Munoz SC, Morphey AS, Bashir Q, Qazilbash MH, Orlowski RZ. Update on a Phase II Study of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood Journal 130(Suppl 1), 2017. e-Pub 2017.
91. Popat UR, Parmar S, Rondon G, Delgado R, Weber DM, Shah JJ, Thomas S, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence. Blood 128(22), 2016. e-Pub 2016.
92. Nooka AK, Wang M, Yee AJ, Thomas SK, O'Donnell EK, Shah JJ, Kaufman JL, Peterkin D. Final Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). Blood 128(22), 2016. e-Pub 2016.
93. Popescu M, Shah N, Bashir Q, Patel K, Shpall EJ, Weber DM, Thomas SK, Shah JJ, Robert Z Orlowski RZ, Kerr N, Al G. Randomized Phase II Trial of Combination Idiotype Vaccine and Anti-CD3/Anti-CD28 Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation. Blood 128(22), 2016. e-Pub 2016.
94. Popat UR, Parmar S, Rondon G, Delgado R, Weber DM, Shah JJ, Thomas S, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH. A Case Control Study of Syngeneic Transplantation Versus Autologous Transplantation for Multiple Myeloma: Two Decades of Experience at MD Anderson. Blood 128(22), 2016. e-Pub 2016.
95. Hu B, Sasaki K, Bashir Q, Shah N, Patel KK, Popat UR, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen JL, Shah JJ, Manasanch EE, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH. Depth of response post autologous hematopoietic stem cell transplantation (auto-HCT) to predict outcome in high risk multiple myeloma (MM). J Clin Oncol 34, 2016. e-Pub 2016.
96. Wang Y, Wagner-Bartak N, Zhou S, Fowler N, Dela Rosa ML, Zhao D, Romaguera JE, Neelapu SS, Hagemeister FB, Fanale MA, Oki Y, Shah JJ, Thomas SK, Hosing CM, Zhang L, Badillo M, Chen W, Cai Q, Zou D, Champlin RE, Fayad LE, Lee HJ, Wang M. Lenalidomide Plus Rituximab for Relapsed or Refractory Diffuse Large B-Cell, Follicular and Transformed Lymphoma: Final Data Analysis of a Phase 2 Trial. Blood 126(23):3969, 2015. e-Pub 2015.
97. Sasaki K, Shah N, Bashir Q, Hosing CM, Popat UR, Nieto Y, Parmar S, Shah JJ, Weber D, Weissinger D, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Light Chain Multiple Myeloma Compared to IgG/IgA Myeloma after Autologous Stem Cell Transplant. Blood 126(23):3194, 2015. e-Pub 2015.
98. Claussen CM, Chuang T, Shah J, Lee H, Shah N, Patel KK, Bashir Q, Parmar S, Thomas S, Qazilbash M, Davis RE, Neelapu SS, Weber D, Orlowski RZ, Feng L, Manasanch EE. Use of Gene Expression Profiling May Predict Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting. Blood 126(23):5390, 2015. e-Pub 2015.
99. Shah JJ, Feng L, Weber D, Thomas SK, Wang M, Turturro F, Qazilbash MH, Shah N, Bashir Q, Popat UR, Manasanch EE, Munoz SC, Landry A, MendozaK, Nieto Y, Champlin RE, Orlowski RZ. Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood 126(23):3155, 2015. e-Pub 2015.
100. Shah JJ, Feng L, et al TS. Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor Filanesib + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood 126(23), 2015. e-Pub 2015.
101. Nooka AK, Wang M, Yee AJ, Thomas SK, O'Donnell EK, Shah JJ, Kaufman JL, Lonial S, Richardson PG, Raje NS. Updated Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM) 126(23):4246, 2015. e-Pub 2015.
102. Thomas SK, Harb WA, Beck JT, Nashat G, Palomba ML, Ansell SM, Eradat H, Libby III EN, Advani RH, Julio Hajdenberg J, Heffner LT, Hoffman J, Vesole DH, Simov L, Wyant N, Brevard J, O'Leary J, Sudhir Agrawal D, *. Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia 126(23):1540, 2015. e-Pub 2015.
103. Wang M, Nooka AK, Yee AJ, Thomas SK, O'Donnell E, Shah J, Weber DM, Kaufman JL, Lonial S, Avigan D, Raje N. Initial Results of a Phase 1/2a, Dose Escalation Study of PVX-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). Blood 124(21), 2014. e-Pub 2014.
104. Shah JJ, Feng L, Manasanch EE, Weber DM, Thomas SK, Turturro F, Alexanian R, Shah N, Popat UR, Nieto Y, Bashir Q, Qazilbash MH, Champlin RE, Orlowski RZ. Phase I/Ib Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. Blood 124(21):187, 2014. e-Pub 2014.
105. Dimopoulos MA, Kastritis E, Owen RG, Kyle RA, Landgren O, Morra E, Leleu X, Garcıa-Sanz R, Munshi N, Anderson KC, Terpos E, Ghobrial IM, Morel P, Maloney D, Rummel M, Leblond V, Advani RH, Gertz MA, Kyriakou C, Thomas SK, Barlogie B, Gregory SA, Kimby E, Merlini G, Treon SP. Treatment recommendations for patients with Waldenstrom¨ macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood 124(21), 2014. e-Pub 2014.
106. Thomas SK, Melendez GA, Fend L, Wang M, Neelapu SS, Shah JJ, Orlowski RZ, Weber DM. Phase I trial of pomalidomide (P) in patients (pts) with relapsed and/or refractory (R/R) Waldenström's macroglobulinemia (WM). J Clin Oncol 32(5s), 2014. e-Pub 2014.
107. Thomas SK, Mendoza TR, Dougherty PM, Williams LA, Wang XS, Prasad S, Shah N, Shah JJ, Wang M, Weber DM, Orlowski RZ, Giralt S, Cleeland CS. A phase 2 trial of minocycline versus placebo to prevent neuropathy in patients (pts) with multiple myeloma (MM). J Clin Oncol(32), 2014. e-Pub 2014.
108. Ocio EM, Thomas SK, Günther A, Lebovic D, Kumar SK, Jakubowiak AJ, Song D, Ziang F, Hynds D, Vanase KG, Goh YT. Phase 1 Study Of The Novel Pan-Pim Kinase Inhibitor LGH447 In Patients With Relapsed/ Refractory Multiple Myeloma. Blood 122(21), 2013. e-Pub 2013.
109. Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M, Weber DM, Orlowski RZ. Evidence of a Role for CD44 and Cell Adhesion in Mediating Resistance to Lenalidomide in Multiple Myeloma: Therapeutic Implications. e-Pub 2013. PMID: 23760401.
110. Alagappan A, Shah R, Thomas SK, Weber DM, Wang M, Alexanian R, Orlowski RZ, Shah JJ. Feasibility and Activity Of Bortezomib-Based Therapy In Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Carfilzomib. Blood 122(21), 2013. e-Pub 2013.
111. Nieto Y, Shah N, Popat UR, Jones RB, Bashir Q, Bassett R, Valdez BC, Andersson BS, Parmar S, Orlowski RZ, Shah JJ, Thomas SK, Wang M, Champlin RE, Qazilbash M. High-Dose Gemcitabine Combined With Busulfan and Melphalan (Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Refractory and Relapsed Myeloma. Blood 122(21), 2013. e-Pub 2013.
112. Shah, JJ, Baladandayuthapani V, Weber DM, Thomas SK, Alexanian R, Wang M, Qazilbash MH, Champlin RE, Shah N, Bashir Q, Popat UR, Nieto Y, Ahmed S, Parmar S, Orlowski RZ. Phase II Study Of The Combination Of MLN 9708 With Lenalidomide As Maintenance Therapy Post Autologous Stem Cell Transplant In Patients With Multiple Myeloma. Blood 122(21), 2013. e-Pub 2013.
113. Shah RA, Mohite S, Baladandayuthapani V, Thomas SK, Weber DM, Wang M, Alexanian R, Qazilbash MH, Popat UR, Champlin RE, Shah N, Bashir Q, Parmar S, Nieto Y, Ahmed S, Orlowski RZ, Shah JJ. Circulating Plasma Cells By Routine Complete Blood Count Identify Patients With Similar Outcome As Plasma Cell Leukemia. Blood 122(21), 2013. e-Pub 2013.
114. Orlowski, RZ, Zaman S, Thomas SK, Alexanian R, Shah JJ, Weber DM, Wang M, Holloway AN, Baladandayuthapani V, Lin HY, Fu M, Stellrecht CM, Morales de Partovi C, Gandhi V. Phase II Study Of The c-MET Inhibitor ARQ 197 (Tivantinib) In Patients With Relapsed Or Relapsed/Refractory Multiple Myeloma (RRMM). Blood 122(21), 2013. e-Pub 2013.
115. Shah JJ, Feng L, Thomas SK, Weber DM, Wang M, Hilder B, Alexanian R, Orlowski R. Phase 1 Study Of The Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib (Car) In Patients With Relapsed and/Or Refractory Multiple Myeloma (RRMM). Blood 122(21), 2013. e-Pub 2013.
116. Treon SP, Tripsas CK, Meid K, Patterson C, Heffner LT, Eradat H, Gregory SA, Thomas SK, Advani RH, Baz R, Badros AZ, Matous J, Murphy TJ, Ghobrial IM. Prospective, Multicenter Study Of The Mtor Inhibitor Everolimus (RAD001) As Primary Therapy In Waldenstrom’s Macroglobulinemia. Blood 122(21), 2013. e-Pub 2013.
117. Patel K, Feng L, Oki Y, Qazilbash M, Muzzafar T, Weber DM, Fowler N, Popat UR, Thomas SK, Fanale MA, Nieto Y, Shah N, Bashir Q, Hagemeister FB, Orlowski RZ, Shah JJ. Plasmablastic Lymphoma: 28 Patient Single Institution Experience. Blood 122(21), 2013. e-Pub 2013.
118. Raab MS, Ocio EM, Thomas SK, Gunther A, Lebovic D, Kumar SK, Jakubowiak AJ, Song D, Xiang F, Hynds D, Vanasse KG, Goh YT. Phase 1 Study Of The Novel Pan-Pim Kinase Inhibitor LGH447 In Patients With Relapsed/ Refractory Multiple Myeloma. Blood 122(21), 2013. e-Pub 2013.
119. Thomas SK, Haygood TM, Qazilbash MH, Melendez A, Galvis R, Delasalle KB, Feng L, Richards TA, Samaniego F, Wang L, Shah JJ, Orlowski RZ, Weber DM. A Phase II Trial Of Bortezomib-Rituximab Followed By Autologous Stem Cell Harvest (SCH) and Cladribine-Cyclophosphamide-Rituximab (2CdA-Cy-Rit) Consolidation As Primary Therapy Of Waldenström's Macroglobulinemia (WM). Blood 122(21), 2013. e-Pub 2013.
120. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood 120(21), 2012. e-Pub 2012.
121. Thomas SK, Mendoza TR, Vichaya EG, Wang XS, Sailors MH, Williams LA, Dougherty PM, Cleeland CS. Validation of the chemotherapy-induced neuropathy assessment scale. J Clin Oncol 30, 2012. e-Pub 2012.
122. Vichaya EG, Wang S, Boyette-Davis JA, Thomas SK, Shah N, Mendoza TR, Williams LA, Cleeland CS, Dougherty PM. Baseline subclinical sensory deficits and the development of pain and numbness in patients with multiple myeloma (MM) being treated with chemotherapy. J Clin Oncol 30, 2012. e-Pub 2012.
123. Reed VK, Shah JJ, Mazloom A, Weber DM, Phan J, Orlowski RZ, Thomas SK, Wang M, Alexanian R, Dabaja BS. Outcome and prognostic factors in solitary plasmacytoma. J Clin Oncol 28(15s), 2010. e-Pub 2010.
124. Thomas SK. ISSMM and IPSSWM as Prognosticators in WM. Venice, Italy, 2010. 6th International Workshop on Waldenstrom's Macroglobulinemia Venice, 2010. e-Pub 2010.
125. Thomas S, Feng L, Delasalle KB, Wang M, Shah JJ, Orlowski RZ, Alexanian R, Weber DM. Prognostic Factors for survival after 2-CdA-based therapy for symptomatic Waldenstrom Macroglobulinemia (WM) stratify patients into low- and high-risk groups. Blood (ASH Annual Meeting Abstracts) 114:1668, 2009. e-Pub 2009.
126. Delasalle KB, Wang L, Weber D, Giralt SA, Thomas S, Shah J, Handy B, Orlowski RZ, Alexanian R. Curability of Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 114:3864, 2009. e-Pub 2009.
127. Shah N, Weber DM, Wang M, Thomas S, Shah J, Giralt S, Alexanian R, Orlowski RZ, Qazilbash MH, and Avery T. Survival Disparities Between African-American and Caucasian Patients with Multiple Myeloma Are Blunted in the Era of Novel Therapeutics and Autologous Stem Cell Transplantation. Blood:1395, 2009. e-Pub 2009.
128. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Korbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, Marcos D, Weber DM, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Blood 15(6):718-23, 2009. e-Pub 2009. PMID: 19450756.
129. Voorhees PM, Manges RF, Somio G, Lentzsch S, Jagannath S, Sonneveld P, Frank RC, Zweegman S, Wijermans PW, Thomas S. A phase II multicenter study of CNTO 328, an anti-IL-6 monoclonal antibody, in patients (pts) with relapsed or refractory multiple myeloma (MM). J Clin Oncol 27(15s), 2009. e-Pub 2009.
130. Shah N, Weber D, Orlowski R, Wang M, Thomas SK, Richards T, Giralt S, Qazilbash M, Alexanian R, Shah JJ. Role of autologous stem cell transplant after induction therapy with bortezomib-lenolidomide or bortezomib-thalidomide in newly diagnosed multiple myeloma patients. J Clin Oncol 27(Suppl):15S, 2009. e-Pub 2009.
131. Thomas S, Hosing C, Delasalle K, Gavino M, Popat U, Qazilbash M, Giralt S, Weber D, Alexanian R. Success rates of autologous stem cell collection in patients with Waldenstrom Macroglobulinemia. 5th International Workshop on Waldenstrom's Macroglobulinemia Stockholm. Sweden 2008, 2008. e-Pub 2008.

Book Chapters

1. Lee HC, Manasanch EE, TS. Multiple Myeloma and other Plasma Cell Dyscrasias. In: The M.D. Anderson Manual of Medical Oncology. McGraw Hill, 229-253, 2016.
2. Thomas S, Wang M, Weber D. Abnormal serum protein electrophoresis. In: Decision Making in Medicine, An Algorithmic Approach. Mosby, Inc, 2010.
3. Thomas S, Richards T, Weber DM. Lenalidomide in relapsed or refractory multiple myeloma. In: Myeloma Myeloma Therapy: Pursuing the Plasma Cell (Contemporary Hematology). The Humana Press, Inc, 2008.
4. Thomas S, Richards T, Weber DM. Novel agents for previously untreated multiple myeloma. In: Multiple Myeloma. Informa Healthcare, 2008.

Letters to the Editor

1. Chohan, KL, Gensini, L, Seif, S, Sun, X, Feng, L, Becnel, M, Gaballa, MM, Lee, HC, Pasvolsky, O, Patel, K, Ye, JC, Weber, DM, Orlowski, R, Thomas, SK. Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy. Blood cancer journal 15, 2025.
2. Louise A, de Mortel JV, Tomkins O, Flinsenberg T, Japzon N, Kersten MJ, Khwaja J, Kuipers S, Levenga H, McKeague S, Opat S, Salvaris R, Seif S, Thomas SK, Vrancken A, D’Sa S, Minnema M, Vos J. Zanubrutinib in Bing-Neel syndrome: Efficacy and Tolerability, 2025.
3. Marcoux C, Pasyar S, Milton DR, Khan HN, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Neupane N, Lee HC, Patel KK, Tang G, Aljawai Y, Kebriaei P, Thomas SK, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH, Pasvolsky O. Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant. Br J Haematol 206: 763-765, 2024.